Transformer-based decision support with CNN and ViT for prognostic risk stratification following adjuvant chemotherapy in high-grade glioma: a multicenter study.
Sep 2026· Computer Methods and Programs in Biomedicine· Vol 288, pp.
109668
· 0 citations· 59 references
Medicine
TL;DR
This approach demonstrates robust, non-invasive performance in stratifying HGG patients into prognostically distinct subgroups with differential survival trajectories following post-radiotherapy TMZ chemotherapy.
Abstract
Background
High-grade gliomas (HGGs) exhibit marked intratumoral heterogeneity, which is associated with variable survival outcomes among patients receiving standard adjuvant chemotherapy. Conventional methods relying on molecular biomarkers are constrained by technical limitations and tumor heterogeneity. This study aimed to develop a multi-channel 2.5D deep learning framework that integrates Convolutional Neural Network (CNN) and Vision Transformer (ViT) features to noninvasively stratify HGG patients based on expected survival outcomes following postoperative adjuvant temozolomide (TMZ) chemotherapy and to explore the underlying molecular mechanisms.
Methods
Multicenter MRI data (T1-CE/T2-FLAIR; n=507) were analyzed using habitat clustering to define tumor subregions. A 2.5D multi-channel strategy was employed to extract features via ResNeXt101_32 × 8d (CNN) and ViT, which were then integrated using a Transformer fusion model. Transcriptomic analyses, including differential expression, gene set enrichment analysis (GSEA), and protein-protein interaction (PPI) network analysis, were performed to biologically validate the imaging-based predictions. Model performance was assessed by the area under the curve (AUC), accuracy, sensitivity, specificity, and survival analysis (Kaplan-Meier/log-rank test).
Results
The fusion model demonstrated superior performance, consistently outperforming both CNN and ViT models across training (AUC = 0.950, 95% CI: 0.917-0.982), internal-test (0.828, 0.720-0.937), and external-validation (0.810, 0.710-0.911) cohorts. Transcriptomic validation confirmed significant enrichment of cell cycle and DNA damage response pathways in the low-risk patient group, with CHEK1, CDK1, and FEN1 identified as key regulatory genes.
Conclusion
This approach demonstrates robust, non-invasive performance in stratifying HGG patients into prognostically distinct subgroups with differential survival trajectories following post-radiotherapy TMZ chemotherapy. The association with DNA damage response pathways provides biological interpretability, supporting prognostic risk stratification and providing a reference for postoperative surveillance planning.
This model identifies patients unlikely to benefit from standard TMZ chemotherapy, providing a tool for postoperative personalized treatment stratification and optimization of therapeutic strategies in HGGs.
Ze-Hui Li, Xin Duan, Jun-Jie Lian et al.· Frontiers in Immunology· 0 citations
The DLRTransformer improved postoperative risk stratification compared with guideline-based risk stratification and identified patients with stage I NSCLC who benefited from adjuvant therapy.
Li-Ying Wang, Yu Zong, Xin-Yu Li et al.· Radiology: Imaging Cancer· 0 citations
Predicting response to induction chemotherapy (IC) and overall survival (OS) is critical for optimizing treatment in patients with locally advanced nasopharyngeal carcinoma (LANPC). This study aimed to develop and validate a multi-task deep learning model integrating pretreatment MRI and whole slide images (WSIs) to pr...
Jing Hou, Xiao-Chun Yi, Cong-Rui Li et al.· PLOS Digital Health· 0 citations
An artificial intelligence (AI)-based deep-learning model enables accurate inference of a clinically validated immune gene-expression program directly from routine H&E slides and is independently associated with survival and pCR to NACT/NACTIT in eBC.
F. Bertucci, Gwenael Lumet, Mathieu Delattre et al.· Journal of Translational Med...· 0 citations
OBJECTIVE
Glioblastoma (GBM) is a lethal tumor where temozolomide (TMZ) chemotherapy often faces resistance. We develop a deep learning model based on a Vision Transformer (ViT) architecture for pretreatment prediction of TMZ resistance.
METHODS
We retrospectively enrolled 314 GBM patients across four centers between...
Cai-Qiang Xue, Sheng-Lin Li, Yu-Feng Li et al.· Academic Radiology· 0 citations
Glioblastoma multiforme (GBM)is one of the most common and lethal forms of brain tumor, with a median overall survival time of being only 12-15 months.GBM is highly heterogeneous meaning that there is considerable variation in tumor characteristics, behavior, and treatment outcomes across patients. This leads to differ...
Asima Majied Wani, M. Chishti, M. A. Wani· International Conference on...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.